Expression of Sox10 and c-kit in Sinonasal Mucosal Melanomas Arising in the Chinese Population

[1]  J. Taube,et al.  Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. , 2012, Journal of the American Academy of Dermatology.

[2]  A. Hauschild,et al.  Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors , 2011, Melanoma research.

[3]  G. McArthur,et al.  Review: mucosal melanoma of the head and neck , 2011, Melanoma research.

[4]  Jinah Kim,et al.  Identification of Nodal Metastases in Melanoma Using Sox-10 , 2011, The American Journal of dermatopathology.

[5]  P. Bradley,et al.  Malignant melanoma of nasal cavity and paranasal sinuses: report of 24 patients and literature review , 2011, The Journal of Laryngology & Otology.

[6]  J. Karamchandani,et al.  SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar , 2010, Journal of cutaneous pathology.

[7]  S. Woodman,et al.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. , 2010, Biochemical pharmacology.

[8]  A. Dobrovic,et al.  Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT , 2010, British Journal of Cancer.

[9]  D. Nonaka,et al.  Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes , 2009, Histopathology.

[10]  S. Woodman,et al.  Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type , 2009, Modern Pathology.

[11]  T. Saida,et al.  Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas , 2009, International journal of cancer.

[12]  R. de Bree,et al.  Head and neck mucosal melanoma: Experience with 42 patients, with emphasis on the role of postoperative radiotherapy , 2008, Head & neck.

[13]  R. Gutzmer,et al.  Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas , 2008, British Journal of Cancer.

[14]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[15]  L. Chiriboga,et al.  Sox10: A Pan-Schwannian and Melanocytic Marker , 2008, The American journal of surgical pathology.

[16]  D. Kutler,et al.  PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck , 2008, Head & neck.

[17]  H. Nagatsuka,et al.  C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma , 2008, Virchows Archiv.

[18]  Narasimhan P. Agaram,et al.  L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition , 2007, International journal of cancer.

[19]  J. Messina,et al.  Primary mucosal melanoma. , 2007, Journal of the American Academy of Dermatology.

[20]  P. Loehrer.  Prevalence of KIT Expression in Human Tumors , 2007 .

[21]  C. Tzen,et al.  Clinical implications of C‐kit gene mutation in patients with large gastrointestinal stromal tumors , 2006, Journal of gastroenterology and hepatology.

[22]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Chopp,et al.  Dopachrome tautomerase (Dct) regulates neural progenitor cell proliferation. , 2006, Developmental biology.

[24]  R. Kelsh.  Sorting out Sox10 functions in neural crest development , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  S. Mills,et al.  Anorectal malignant melanoma: morphologic and immunohistochemical features. , 2006, American journal of clinical pathology.

[26]  X. Mirabel,et al.  Primary Mucosal Melanoma of Head and Neck: Prognostic Value of Clear Margins , 2006, The Laryngoscope.

[27]  L. Layfield,et al.  BRAF and c-kit gene copy number in mutation-positive malignant melanoma. , 2006, Human pathology.

[28]  Kevin B. Kim,et al.  Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM) , 2006, Journal of cutaneous pathology.

[29]  Y. Jeng,et al.  HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas. , 2005, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[30]  J. Lutzky,et al.  An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients , 2005, Melanoma research.

[31]  Yi-Chuan Cheng,et al.  Sox group E gene expression distinguishes different types and maturational stages of glial cells in developing chick and mouse. , 2005, Brain research. Developmental brain research.

[32]  W. Gerald,et al.  Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. , 2005, Neoplasia.

[33]  S. Tripp,et al.  Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. , 2005, Human pathology.

[34]  F. Mascarelli,et al.  Roles of Stem Cell Factor/c-Kit and Effects of Glivec®/STI571 in Human Uveal Melanoma Cell Tumorigenesis* , 2004, Journal of Biological Chemistry.

[35]  J. Myers,et al.  Melanoma of the head and neck: current concepts in staging, diagnosis, and management. , 2004, Surgical oncology clinics of North America.

[36]  C. O'brien,et al.  Current management of mucosal melanoma of the head and neck , 2003, Journal of surgical oncology.

[37]  L. Thompson,et al.  Sinonasal Tract and Nasopharyngeal Melanomas: A Clinicopathologic Study of 115 Cases With a Proposed Staging System , 2003, The American journal of surgical pathology.

[38]  B. Vincenzi,et al.  Prevention of radiotherapy-induced emesis. , 2003, Journal of experimental & clinical cancer research : CR.

[39]  G. Fiorentini,et al.  Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial. , 2003, Journal of experimental & clinical cancer research : CR.

[40]  J. Shah,et al.  Primary mucosal malignant melanoma of the head and neck , 2002, Head & neck.

[41]  E. Abraham,et al.  Primary malignant mucosal melanoma of the head and neck region: pooled analysis of 60 published cases from India and review of literature , 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[42]  W. Pavan,et al.  Analysis of SOX10 function in neural crest-derived melanocyte development: SOX10-dependent transcriptional control of dopachrome tautomerase. , 2001, Developmental biology.

[43]  A. Huvos,et al.  Expression of Melanocytic Differentiation Markers in Malignant Melanomas of the Oral and Sinonasal Mucosa , 2001, The American journal of surgical pathology.

[44]  P. Blume-Jensen,et al.  Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction , 1999, Oncogene.

[45]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.

[46]  K. Togawa,et al.  [Mucosal melanomas of the head and neck]. , 1988, Nihon Jibiinkoka Gakkai kaiho.

[47]  C. Koopmann,et al.  Mucosal melanoma of the head and neck , 1986, The Laryngoscope.